MX366055B - Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno. - Google Patents
Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.Info
- Publication number
- MX366055B MX366055B MX2014002203A MX2014002203A MX366055B MX 366055 B MX366055 B MX 366055B MX 2014002203 A MX2014002203 A MX 2014002203A MX 2014002203 A MX2014002203 A MX 2014002203A MX 366055 B MX366055 B MX 366055B
- Authority
- MX
- Mexico
- Prior art keywords
- rna
- immunogen
- polyethylene glycol
- liposome
- delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un liposoma dentro del cual se encapsula ARN que codifica para un polipéptido inmunogénico de interés, caracterizado porque comprende al menos un lípido que es modificado por una unión covalente de una porción de polietilenglicol, tal que el polietilenglicol está presente en el exterior del liposoma, en donde la masa molecular promedio del polietilenglicol está por arriba de 3kDa pero es menos de 11 kDa y en donde el liposoma no contiene ribosomas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161529878P | 2011-08-31 | 2011-08-31 | |
PCT/US2012/053391 WO2013033563A1 (en) | 2011-08-31 | 2012-08-31 | Pegylated liposomes for delivery of immunogen-encoding rna |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014002203A MX2014002203A (es) | 2014-05-30 |
MX366055B true MX366055B (es) | 2019-06-26 |
Family
ID=47003206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014002203A MX366055B (es) | 2011-08-31 | 2012-08-31 | Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno. |
Country Status (21)
Country | Link |
---|---|
US (3) | US20140255472A1 (es) |
EP (2) | EP2750707B1 (es) |
JP (1) | JP2014525461A (es) |
CN (1) | CN103974719A (es) |
AU (1) | AU2012301715B2 (es) |
BR (1) | BR112014004607A2 (es) |
CA (1) | CA2846043A1 (es) |
CY (1) | CY1121122T1 (es) |
DK (1) | DK2750707T3 (es) |
ES (1) | ES2705498T3 (es) |
HR (1) | HRP20190032T1 (es) |
HU (1) | HUE041800T2 (es) |
LT (1) | LT2750707T (es) |
MX (1) | MX366055B (es) |
PL (1) | PL2750707T3 (es) |
PT (1) | PT2750707T (es) |
RU (1) | RU2628705C2 (es) |
SG (2) | SG10201602456WA (es) |
SI (1) | SI2750707T1 (es) |
TR (1) | TR201900264T4 (es) |
WO (1) | WO2013033563A1 (es) |
Families Citing this family (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10487332B2 (en) | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
EP3243526B1 (en) | 2010-07-06 | 2019-11-27 | GlaxoSmithKline Biologicals S.A. | Delivery of rna to trigger multiple immune pathways |
CN103052400B (zh) | 2010-07-06 | 2016-11-16 | 诺华股份有限公司 | 自我复制rna分子的病毒样递送颗粒 |
SI2590626T1 (sl) | 2010-07-06 | 2016-01-29 | Glaxosmithkline Biologicals S.A. | Liposomi z lipidi, ki imajo koristno pKa vrednost, za dostavo RNA |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
HRP20230185T8 (hr) | 2010-08-31 | 2023-07-21 | Glaxosmithkline Biologicals Sa | Pegilirani liposomi za isporuku rna koja kodira imunogen |
HUE059214T2 (hu) | 2010-08-31 | 2022-10-28 | Glaxosmithkline Biologicals Sa | Kis liposzómák immunogént kódoló RNA bejuttatására |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
JP2013544504A (ja) | 2010-10-11 | 2013-12-19 | ノバルティス アーゲー | 抗原送達プラットフォーム |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
BR112013031553A2 (pt) | 2011-06-08 | 2020-11-10 | Shire Human Genetic Therapies, Inc. | composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena |
EP2729165B1 (en) | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP4015005A1 (en) | 2011-10-03 | 2022-06-22 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
SG11201402666WA (en) | 2011-12-16 | 2014-10-30 | Moderna Therapeutics Inc | Modified nucleoside, nucleotide, and nucleic acid compositions |
AU2013243955B2 (en) | 2012-04-02 | 2018-02-22 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9683022B2 (en) | 2012-07-06 | 2017-06-20 | Glaxosmithkline Biologicals S.A. | Complexes of cytomegalovirus proteins |
WO2014028429A2 (en) | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
RU2015132962A (ru) | 2013-01-10 | 2017-02-14 | Новартис Аг | Иммуногенные композиции на основе вируса гриппа и их применение |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
CN105980401A (zh) | 2013-10-03 | 2016-09-28 | 现代治疗公司 | 编码低密度脂蛋白受体的多核苷酸 |
EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
ES2844208T3 (es) | 2014-03-25 | 2021-07-21 | Univ Yale | Usos de los factores inhibidores de la migración de macrófagos parásitos |
RU2016143591A (ru) | 2014-04-08 | 2018-05-08 | Арадайм Корпорейшн | Липосомы, в которых образуются нанокристаллы лекарственного вещества после замораживания-оттаивания |
AU2015244275B2 (en) | 2014-04-08 | 2019-08-29 | Aradigm Corporation | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
AU2015289583A1 (en) | 2014-07-16 | 2017-02-02 | Modernatx, Inc. | Chimeric polynucleotides |
EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
US20190008938A1 (en) | 2015-07-30 | 2019-01-10 | Modernatx, Inc. | Concatemeric peptide epitope rnas |
CA2998810A1 (en) | 2015-09-17 | 2017-03-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
US10548959B2 (en) | 2015-09-23 | 2020-02-04 | Massachusetts Institute Of Technology | Compositions and methods for modified dendrimer nanoparticle delivery |
WO2017062513A1 (en) | 2015-10-05 | 2017-04-13 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
LT3386484T (lt) | 2015-12-10 | 2022-06-10 | Modernatx, Inc. | Gydomųjų medžiagų sudėtis ir pristatymo metodai |
EP4036079A3 (en) | 2015-12-22 | 2022-09-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
WO2017123315A2 (en) * | 2016-01-12 | 2017-07-20 | Aradigm Corporation | Nanocrystals formed in a microenvironment |
WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
AU2017268394A1 (en) | 2016-05-18 | 2019-01-03 | Modernatx, Inc. | Polynucleotides encoding relaxin |
WO2017208191A1 (en) | 2016-06-02 | 2017-12-07 | Glaxosmithkline Biologicals Sa | Zika viral antigen constructs |
WO2017220099A1 (en) | 2016-06-24 | 2017-12-28 | Statens Serum Institut | Adjuvants with modified drainage properties |
WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
EP4043031A3 (en) | 2016-11-17 | 2022-11-23 | GlaxoSmithKline Biologicals SA | Zika viral antigen constructs |
AU2017397458A1 (en) * | 2017-02-01 | 2019-08-15 | Modernatx, Inc. | RNA cancer vaccines |
AU2018234814B2 (en) | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
EP3609534A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | BROAD SPECTRUM VACCINE AGAINST THE INFLUENZA VIRUS |
EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS VACCINE |
EP3595727A1 (en) | 2017-03-15 | 2020-01-22 | ModernaTX, Inc. | Lipid nanoparticle formulation |
EP3596041B1 (en) | 2017-03-15 | 2022-11-02 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
BR112019023477A2 (pt) | 2017-05-08 | 2020-06-30 | Gritstone Oncology, Inc. | vetores de neoantígeno de alfavírus |
EP3638678A1 (en) | 2017-06-14 | 2020-04-22 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
WO2019008001A1 (en) | 2017-07-04 | 2019-01-10 | Curevac Ag | NEW NUCLEIC ACID MOLECULES |
US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
AU2018326799A1 (en) * | 2017-08-31 | 2020-02-27 | Modernatx, Inc. | Methods of making lipid nanoparticles |
JP7389741B2 (ja) | 2017-09-13 | 2023-11-30 | バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー | T細胞受容体または人工t細胞受容体を発現するためのrnaレプリコン |
EP3681993A1 (en) | 2017-09-13 | 2020-07-22 | BioNTech RNA Pharmaceuticals GmbH | Rna replicon for reprogramming somatic cells |
EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
AU2018379379A1 (en) * | 2017-12-06 | 2020-06-18 | Newsouth Innovations Pty Limited | Liposomal system for drug delivery |
CA3087537A1 (en) | 2018-01-04 | 2019-07-11 | Jan-willem THEUNISSEN | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods |
JP2021534182A (ja) | 2018-08-17 | 2021-12-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物及びその使用 |
EP3852728B1 (en) | 2018-09-20 | 2024-09-18 | ModernaTX, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
AU2019359299B2 (en) | 2018-10-09 | 2022-04-21 | The University Of British Columbia | Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto |
WO2020144295A1 (en) | 2019-01-10 | 2020-07-16 | Biontech Rna Pharmaceuticals Gmbh | Localized administration of rna molecules for therapy |
KR20210113655A (ko) | 2019-01-10 | 2021-09-16 | 얀센 바이오테크 인코포레이티드 | 전립선 신생항원 및 이의 용도 |
SG11202113187WA (en) | 2019-05-30 | 2021-12-30 | Gritstone Bio Inc | Modified adenoviruses |
CA3141323A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Recombinant interleukin 12 construct and uses thereof |
AU2020295012A1 (en) | 2019-06-18 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis B virus (HBV) vaccines and anti-PD-1 or anti-PD-L1 antibody |
WO2020255010A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
EP3986562A1 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
US20220233685A1 (en) | 2019-06-18 | 2022-07-28 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
TW202114732A (zh) | 2019-06-20 | 2021-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 遞送b型肝炎病毒(hbv)疫苗之脂質奈米顆粒或脂質體 |
US20220273789A1 (en) | 2019-07-21 | 2022-09-01 | Glaxosmithkline Biologicals Sa | Therapeutic viral vaccine |
US11066355B2 (en) | 2019-09-19 | 2021-07-20 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
EP3819377A1 (en) | 2019-11-08 | 2021-05-12 | Justus-Liebig-Universität Gießen | Circular rna and uses thereof for inhibiting rna-binding proteins |
BR112022009598A2 (pt) | 2019-11-18 | 2022-08-16 | Janssen Biotech Inc | Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos |
US20240277830A1 (en) | 2020-02-04 | 2024-08-22 | CureVac SE | Coronavirus vaccine |
EP3865122A1 (en) * | 2020-02-11 | 2021-08-18 | Pantherna Therapeutics GmbH | Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium |
AU2021233816A1 (en) | 2020-03-09 | 2022-10-06 | Arcturus Therapeutics, Inc. | Coronavirus vaccine compositions and methods |
CA3172591A1 (en) | 2020-03-24 | 2021-09-30 | Douglas Anthony KERR | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
US20230138409A1 (en) | 2020-03-24 | 2023-05-04 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing factor ix therapeutics |
WO2021209970A1 (en) | 2020-04-16 | 2021-10-21 | Glaxosmithkline Biologicals Sa | Sars cov-2 spike protein construct |
CA3181193A1 (en) | 2020-06-04 | 2021-12-09 | Mario Perkovic | Rna replicon for versatile and efficient gene expression |
US20230234992A1 (en) | 2020-06-05 | 2023-07-27 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
EP4171629A1 (en) | 2020-06-29 | 2023-05-03 | GlaxoSmithKline Biologicals S.A. | Adjuvants |
JP2023533528A (ja) | 2020-07-08 | 2023-08-03 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Hbvに対するrnaレプリコンワクチン |
BR112023001648A2 (pt) | 2020-07-27 | 2023-04-04 | Anjarium Biosciences Ag | Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo |
IL300026A (en) | 2020-08-06 | 2023-03-01 | Gritstone Bio Inc | Multiepitope vaccine cassettes |
EP4008785A1 (en) | 2020-12-03 | 2022-06-08 | Justus-Liebig-Universität Gießen | Circular nucleic acids and uses thereof for interfering with genome expression and proliferation of coronaviruses |
TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
KR20230164648A (ko) | 2020-12-22 | 2023-12-04 | 큐어백 에스이 | SARS-CoV-2 변이체에 대한 RNA 백신 |
WO2022137128A2 (en) | 2020-12-23 | 2022-06-30 | Glaxosmithkline Biologicals Sa | Self-amplifying messenger rna |
JP2024501022A (ja) | 2020-12-28 | 2024-01-10 | アークトゥルス セラピューティクス, インコーポレイテッド | Hbvを標的とする転写活性化因子様エフェクターヌクレアーゼ(talen) |
EP4032546A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Therapeutic viral vaccine |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
MX2023011400A (es) | 2021-03-26 | 2023-10-09 | Glaxosmithkline Biologicals Sa | Composiciones inmunogenicas. |
EP4321504A1 (en) * | 2021-04-08 | 2024-02-14 | Xiamen Sinopeg Biotech Co., Ltd. | Pegylated lipid and liposome modified thereby, and pharmaceutical composition comprising liposome and preparation and use thereof |
AU2022260111A1 (en) | 2021-04-20 | 2023-11-30 | Anjarium Biosciences Ag | Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof |
AU2022264509A1 (en) | 2021-04-27 | 2023-12-14 | Generation Bio Co. | Non-viral dna vectors expressing therapeutic antibodies and uses thereof |
US20240216535A1 (en) | 2021-04-27 | 2024-07-04 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
WO2022248353A1 (en) | 2021-05-24 | 2022-12-01 | Glaxosmithkline Biologicals Sa | Adjuvants |
EP4352247A1 (en) | 2021-06-09 | 2024-04-17 | GlaxoSmithKline Biologicals s.a. | Release assay for determining potency of self-amplifying rna drug product and methods for using |
WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023021427A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
EP4396355A1 (en) | 2021-09-03 | 2024-07-10 | GlaxoSmithKline Biologicals S.A. | Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids |
WO2023066875A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Modified replicable rna and related compositions and their use |
AU2022372325A1 (en) | 2021-10-18 | 2024-05-02 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
KR20240107139A (ko) | 2021-11-08 | 2024-07-08 | 오나 테라퓨틱스, 인코포레이티드 | 원형 폴리뉴클레오티드를 전달하기 위한 지질 나노입자 조성물 |
WO2023135273A2 (en) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
WO2023177655A1 (en) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
WO2023218420A1 (en) | 2022-05-13 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Mrna compositions for inducing latent hiv-1 reversal |
WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
WO2023239756A1 (en) | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
WO2023242817A2 (en) | 2022-06-18 | 2023-12-21 | Glaxosmithkline Biologicals Sa | Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2 |
WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
WO2024102730A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and nanoparticle compositions for delivering polynucleotides |
WO2024102677A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Circular rna compositions |
WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
WO2024119103A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
WO2024119051A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same |
WO2024119074A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Stealth lipid nanoparticle compositions for cell targeting |
WO2024119039A2 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Stealth lipid nanoparticles and uses thereof |
WO2024133160A1 (en) | 2022-12-19 | 2024-06-27 | Glaxosmithkline Biologicals Sa | Hepatitis b compositions |
WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE397097T1 (de) * | 1995-03-17 | 2008-06-15 | Wayne John Cancer Inst | Nachweis von brustmetastasen unter verwendung eines mehrfachmarker-tests |
WO2000003683A2 (en) | 1998-07-20 | 2000-01-27 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
DE69943068D1 (de) * | 1999-09-09 | 2011-02-03 | Curevac Gmbh | Transfer von mRNA unter Verwendung von polykationischen Verbindungen |
AU7542301A (en) | 2000-06-09 | 2001-12-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes<sup>TM</sup>) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
EP1297005B1 (en) | 2000-07-03 | 2009-08-26 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation against chlamydia pneumoniae |
NZ524888A (en) | 2000-10-27 | 2006-09-29 | Chiron S | Nucleic acids and proteins from streptococcus groups A & B |
CA2458854A1 (en) | 2001-08-31 | 2003-03-06 | Chiron Srl | Helicobacter pylori vaccination |
AU2003245160B2 (en) | 2002-06-28 | 2009-09-24 | Arbutus Biopharma Corporation | Method and apparatus for producing liposomes |
JP4896715B2 (ja) | 2003-06-26 | 2012-03-14 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Chlamydiatrachomatisに対する免疫原性組成物 |
ES2505695T3 (es) | 2003-07-31 | 2014-10-10 | Novartis Vaccines And Diagnostics, Inc. | Composiciones inmunógenas para Streptococcus pyogenes |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
ES2321212T3 (es) | 2004-05-18 | 2009-06-03 | Alphavax, Inc. | Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion. |
EP1766094A4 (en) * | 2004-05-18 | 2009-11-25 | Vical Inc | INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE |
EP1766034B1 (en) * | 2004-05-21 | 2014-03-19 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for influenza virus vaccines |
CA2569645C (en) * | 2004-06-07 | 2014-10-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
AU2005252273B2 (en) | 2004-06-07 | 2011-04-28 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
ES2385045T3 (es) | 2005-02-18 | 2012-07-17 | Novartis Vaccines And Diagnostics, Inc. | Inmunógenos de Escherichia coli uropatogénica |
US8758764B2 (en) | 2005-02-18 | 2014-06-24 | Novartis Vaccines And Diagnostics Srl | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli |
NZ562381A (en) | 2005-03-30 | 2011-06-30 | Novartis Vaccines & Diagnostic | Haemophilus influenzae type B |
CA2608278A1 (en) | 2005-05-12 | 2006-12-28 | Guido Grandi | Immunogenic compositions for chlamydia trachomatis |
WO2007049155A2 (en) | 2005-10-25 | 2007-05-03 | Novartis Vaccines And Diagnostics Srl | Compositions comprising yersinia pestis antigens |
US20090253778A1 (en) * | 2006-06-21 | 2009-10-08 | Reisfeld Ralph A | DNA composition against tumor stromal antigen FAP and methods of use thereof |
US20100166788A1 (en) | 2006-08-16 | 2010-07-01 | Novartis Vaccines And Diagnostics | Immunogens from uropathogenic escherichia coli |
SI2494993T1 (sl) | 2007-05-04 | 2019-01-31 | Marina Biotech, Inc. | Aminokislinski lipidi in njihove uporabe |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
GB0717187D0 (en) | 2007-09-04 | 2007-10-17 | Novartis Ag | Compositions comprising yersinia pestis antigens |
WO2009086558A1 (en) * | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
ITMI20081249A1 (it) | 2008-07-09 | 2010-01-09 | Novartis Vaccines & Diagnostic | Immunogeni di escherichia coli con solubilità migliorata. |
WO2009109860A2 (en) | 2008-03-06 | 2009-09-11 | Novartis Ag | Mutant forms of chlamydia htra |
WO2009132131A1 (en) | 2008-04-22 | 2009-10-29 | Alnylam Pharmaceuticals, Inc. | Amino lipid based improved lipid formulation |
EP2391343B1 (en) * | 2009-01-29 | 2017-03-01 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
CA3154626A1 (en) | 2009-04-14 | 2010-10-21 | Glaxosmithkline Biologicals S.A. | Compositions for immunising against staphylococcus aureus |
WO2011005799A2 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
BR112012001666A2 (pt) * | 2009-07-15 | 2019-09-24 | Novartis Ag | composições de proteína rsv f e métodos para fazer as mesmas |
EP2467357B1 (en) * | 2009-08-20 | 2016-03-30 | Sirna Therapeutics, Inc. | Novel cationic lipids with various head groups for oligonucleotide delivery |
CA2817014A1 (en) | 2009-11-04 | 2011-05-12 | Marina Biotech, Inc. | Activity generating delivery molecules |
EP2516010A2 (en) * | 2009-12-23 | 2012-10-31 | Novartis AG | Lipids, lipid compositions, and methods of using them |
JP2013531634A (ja) * | 2010-05-24 | 2013-08-08 | メルク・シャープ・エンド・ドーム・コーポレイション | オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質 |
US9770463B2 (en) * | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
CN103052400B (zh) | 2010-07-06 | 2016-11-16 | 诺华股份有限公司 | 自我复制rna分子的病毒样递送颗粒 |
SI2590626T1 (sl) | 2010-07-06 | 2016-01-29 | Glaxosmithkline Biologicals S.A. | Liposomi z lipidi, ki imajo koristno pKa vrednost, za dostavo RNA |
HUE059214T2 (hu) * | 2010-08-31 | 2022-10-28 | Glaxosmithkline Biologicals Sa | Kis liposzómák immunogént kódoló RNA bejuttatására |
HRP20230185T8 (hr) | 2010-08-31 | 2023-07-21 | Glaxosmithkline Biologicals Sa | Pegilirani liposomi za isporuku rna koja kodira imunogen |
US8584462B2 (en) * | 2011-07-21 | 2013-11-19 | Kalex, Llc | Process and power system utilizing potential of ocean thermal energy conversion |
-
2012
- 2012-08-31 RU RU2014112220A patent/RU2628705C2/ru active
- 2012-08-31 CN CN201280052386.XA patent/CN103974719A/zh active Pending
- 2012-08-31 SG SG10201602456WA patent/SG10201602456WA/en unknown
- 2012-08-31 WO PCT/US2012/053391 patent/WO2013033563A1/en active Application Filing
- 2012-08-31 MX MX2014002203A patent/MX366055B/es active IP Right Grant
- 2012-08-31 AU AU2012301715A patent/AU2012301715B2/en active Active
- 2012-08-31 JP JP2014528651A patent/JP2014525461A/ja active Pending
- 2012-08-31 SI SI201231501T patent/SI2750707T1/sl unknown
- 2012-08-31 ES ES12769787T patent/ES2705498T3/es active Active
- 2012-08-31 PL PL12769787T patent/PL2750707T3/pl unknown
- 2012-08-31 EP EP12769787.8A patent/EP2750707B1/en not_active Revoked
- 2012-08-31 LT LTEP12769787.8T patent/LT2750707T/lt unknown
- 2012-08-31 HU HUE12769787A patent/HUE041800T2/hu unknown
- 2012-08-31 EP EP18201799.6A patent/EP3508220A1/en active Pending
- 2012-08-31 TR TR2019/00264T patent/TR201900264T4/tr unknown
- 2012-08-31 CA CA 2846043 patent/CA2846043A1/en active Pending
- 2012-08-31 BR BR112014004607A patent/BR112014004607A2/pt not_active Application Discontinuation
- 2012-08-31 SG SG11201400250UA patent/SG11201400250UA/en unknown
- 2012-08-31 DK DK12769787.8T patent/DK2750707T3/en active
- 2012-08-31 US US14/240,020 patent/US20140255472A1/en not_active Abandoned
- 2012-08-31 PT PT12769787T patent/PT2750707T/pt unknown
-
2019
- 2019-01-04 HR HRP20190032TT patent/HRP20190032T1/hr unknown
- 2019-01-15 CY CY191100050T patent/CY1121122T1/el unknown
- 2019-12-16 US US16/714,877 patent/US20200113830A1/en not_active Abandoned
-
2023
- 2023-02-27 US US18/114,434 patent/US20240016736A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SI2750707T1 (sl) | 2019-02-28 |
US20240016736A1 (en) | 2024-01-18 |
HRP20190032T1 (hr) | 2019-02-22 |
EP2750707A1 (en) | 2014-07-09 |
SG11201400250UA (en) | 2014-03-28 |
TR201900264T4 (tr) | 2019-02-21 |
EP2750707B1 (en) | 2018-10-24 |
ES2705498T3 (es) | 2019-03-25 |
RU2014112220A (ru) | 2015-10-10 |
CN103974719A (zh) | 2014-08-06 |
JP2014525461A (ja) | 2014-09-29 |
EP3508220A1 (en) | 2019-07-10 |
PT2750707T (pt) | 2019-01-23 |
MX2014002203A (es) | 2014-05-30 |
US20200113830A1 (en) | 2020-04-16 |
WO2013033563A1 (en) | 2013-03-07 |
SG10201602456WA (en) | 2016-04-28 |
LT2750707T (lt) | 2019-01-10 |
AU2012301715A1 (en) | 2014-03-13 |
AU2012301715B2 (en) | 2017-08-24 |
DK2750707T3 (en) | 2019-02-11 |
US20140255472A1 (en) | 2014-09-11 |
CA2846043A1 (en) | 2013-03-07 |
PL2750707T3 (pl) | 2019-05-31 |
RU2628705C2 (ru) | 2017-08-21 |
CY1121122T1 (el) | 2019-12-11 |
BR112014004607A2 (pt) | 2017-03-21 |
HUE041800T2 (hu) | 2019-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX366055B (es) | Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno. | |
MX341989B (es) | Liposomas pequeños para el suministro de arn que codifica el inmunogeno. | |
BR112013004866A2 (pt) | lipossomas peguilados para entrega de rna de imunogénio codificado | |
Aldosari et al. | Lipid nanoparticles as delivery systems for RNA-based vaccines | |
WO2011141705A8 (en) | Novel cationic lipids and methods of use thereof | |
WO2012031046A3 (en) | Lipids suitable for liposomal delivery of protein-coding rna | |
AU2017279565B2 (en) | RNA formulation for immunotherapy | |
WO2012006376A3 (en) | Virion-like delivery particles for self-replicating rna molecules | |
WO2010048536A3 (en) | Processes for preparing lipids | |
BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
US10081598B2 (en) | Cationic lipid | |
JP2014529328A5 (es) | ||
NZ622843A (en) | Improved lipid formulation | |
NZ718817A (en) | Lipid formulations for delivery of messenger rna | |
WO2009086504A3 (en) | Collagen formulations for improved skin care | |
IN2014DN00277A (es) | ||
TW202333780A (zh) | 冠狀病毒疫苗 | |
EA201591188A1 (ru) | Доставка глатирамера ацетата через слизистую оболочку | |
WO2012174091A3 (en) | PERSONAL CARE COMPOSITIONS COMPRISING A pH TUNEABLE GELLANT AND METHODS OF USING | |
WO2011064558A3 (en) | Pharmaceutical composition | |
Firdaus et al. | Liposomal formulations of a polyleucine–antigen conjugate as therapeutic vaccines against cervical cancer | |
WO2014178789A9 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
WO2011143271A3 (en) | Therapeutic liposomes and methods for producing and using the same | |
WO2008063555A3 (en) | Methods of enhancing immune response using electroporation-assisted vaccination and boosting | |
Wang et al. | Trivalent mRNA Vaccine against SARS-CoV-2 and Variants with Effective Immunization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |